Rapamycin dosage
Phase 2Biologic
Rapamycin dosage is one of 10 biologic programs targeting Lymphatic Malformation. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Lymphatic Malformation
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbPhase 2
Piqray
NovartisPhase 2
Viagra
VViatris Specialty LLC
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Rapamycin
MMaastricht Radiation Oncology
Phase 2
TARA-002
PProtara Therapeutics
Phase 2
PTX-022
PPalvella Therapeutics, Inc.
Phase 2
Selenium
SSWOG Cancer Research Network
Phase 1
Rapamycin dosage
UUniversity Hospital, Lille
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rapamycin dosage. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Lille